Suppr超能文献

剖析药物洗脱支架和药物涂层球囊在心血管革命中的进展和潜力。

Unravelling the progress and potential of drug-eluting stents and drug-coated balloons in cardiological insurgencies.

机构信息

University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.

University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India.

出版信息

Life Sci. 2024 Sep 1;352:122908. doi: 10.1016/j.lfs.2024.122908. Epub 2024 Jul 14.

Abstract

AIM

Coronary artery disease (CAD) is the leading cause of mortality. Though percutaneous transluminal angioplasty followed by stenting is still the default treatment of choice for revascularization of obstructive CAD, the high rate of restenosis compromises the outcomes of endovascular procedures. To overcome restenosis, drug-eluting stents (DES) and drug-coated balloons (DCB) are designed that release antiproliferative drugs like sirolimus, paclitaxel, everolimus, etc., over time to inhibit cell growth and proliferation. Our review aims to summarize the challenges and progress of DES/DCBs in clinical settings.

MATERIAL AND METHODS

The comprehensive review, search and selection encompasses in relevant articles through Google Scholar, Springer online, Cochrane library and PubMed that includes research articles, reviews, letters and communications, various viewpoints, meta-analyses, randomized trials and quasi-randomized trials. Several preclinical and clinical data have been included from National Institutes of Health and clinicaltrials.gov websites.

KEY FINDINGS

Challenges like delayed endothelialization, stent thrombosis (ST), and inflammation was prominent in first-generation DES. Second-generation DES with improved designs and drug coatings enhanced biocompatibility with fewer complications. Gradual absorption of bioresorbable DES over time mitigated long-term issues associated with permanent implants. Polymer-free DES addressed the inflammation concerns but still, they leave behind metallic stents in the vasculature. As an alternative therapeutic strategy, DCB were developed to minimize inflammation in the vessel. Although both DES and DCBs have shown considerable progress, challenges persist.

SIGNIFICANCE

This review illustrates the advancements in the designs, preparation technologies, biodegradable materials, and drugs used as well as challenges associated with DES and DCBs in clinical settings.

摘要

目的

冠心病(CAD)是主要的死亡原因。尽管经皮腔内血管成形术加支架置入术仍然是治疗阻塞性 CAD 血运重建的首选方法,但再狭窄率高会影响血管内手术的结果。为了克服再狭窄,设计了药物洗脱支架(DES)和药物涂层球囊(DCB),它们会随着时间的推移释放西罗莫司、紫杉醇、依维莫司等抗增殖药物,以抑制细胞生长和增殖。我们的综述旨在总结 DES/DCB 在临床环境中的挑战和进展。

材料和方法

全面的综述、搜索和选择涵盖了通过 Google Scholar、Springer online、Cochrane library 和 PubMed 搜索的相关文章,包括研究文章、综述、信件和通讯、各种观点、荟萃分析、随机试验和准随机试验。还从美国国立卫生研究院和 clinicaltrials.gov 网站中包括了一些临床前和临床数据。

主要发现

第一代 DES 中存在延迟内皮化、支架血栓形成(ST)和炎症等问题。第二代 DES 具有改进的设计和药物涂层,提高了生物相容性,并发症较少。随着时间的推移,生物可吸收 DES 的逐渐吸收减轻了与永久性植入物相关的长期问题。无聚合物 DES 解决了炎症问题,但它们仍然在血管中留下金属支架。作为替代治疗策略,开发了 DCB 以最大限度地减少血管中的炎症。尽管 DES 和 DCB 都取得了相当大的进展,但挑战仍然存在。

意义

本综述说明了 DES 和 DCB 在临床环境中的设计、制备技术、可生物降解材料和药物的应用以及相关挑战方面的进展。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验